MSB

2.08%

94.0¢ mesoblast limited

Fancy describing compassionate use for years as bad...

First 17890 Last

Share
Profile

Follow
nippy

11,606 Posts.

739

11/08/24

13:32

Post #: 75158307
Share

Originally posted by JB1975: ↑

I picked up your reference - col69 (a person who I'd hope has a below decks cabin) on this ship - and be handcupped to quite a few others - constantly flogs that line - do you remember the original post of mine that actually did think there was a typo even.

I say this because you have been a person who is short and pithy with their posts and doesn't normally attack other posters - you have been rare on hotcopper in that on balance I think your contribution has been positive not self indulgent.

In vivo and in vitro are not used inappropriately in my view in this post - reg's faith that the IL-2R potency assay wasn't used before though is clearly incorrect as any checking of the MSB submission to ODAC using the wayback machine can make clear - MSB has ALWAYS used both TNFR1 and Il2Ralpha.

I am watching the patent applications - an application is not a patent granted. It seems that if I don't post for a while people that don't even tick if I reply to their questions start to try to use some of what I've taught them.

My attitude - there is a lot of people that are going to deserve what they get that are holders on this forum. Character matters.

People of low character - set the bar low.

I'll ask this as a question - Silviu Itsecu was looking for a BLA in August 2020 and got a CRL in October 2020. Eric Rose made public information about a potency assay having problems in May 2022 (could have been 3).

Two questions - do you think Silviu would have been ignorant of the potency assay problem Eric spoke about in May years later at the time of ODAC? Do you think he would have not gone ahead and shipped product that may not have been potent to children even if he was confident its wasn't harmful?

The financial incentives here are a problem in my opinion when coupled to the character of the man. I think the FDA should not dare trust him. He should have to produce evidence ahead of not after a granted BLA because of how he conducts himself in the public sphere. That is my opinion. He can't be trusted to do the right thing - on his own honor- unless he is under close scrutiny to ensure he does. And overwhelmingly that also applies to his supporters here. Medicines would be crap if the objectivity of MSB holders was the standard. The holders themselves would get crap when they need it because their own standards of decency and objectivity - generalised over other people - would have killed them.

Expand

Fancy describing compassionate use for years as bad behaviour.

Fancy describing shareholder's going with non toxic treatment with great 4 year survival data as being of low character as well.

Some mothers do have em.

MSB Price at posting: 95.0¢ Sentiment: Buy Disclosure: Held
17 Upvote

2 Great analysis

Reply

Top Stories

NAM

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

VUL

Vulcan appoints investment bank and M&A veteran to board

MLS

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

ASN

Utah authorities sign off on Anson's lithium extraction plans at Green River

ENV

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

AZY

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

MKG

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

MM8

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

There are more pages in this discussion • 163 more messages in this thread...

First 17890 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 94.0¢		Change -0.020(2.08%)		Mkt cap ! $1.073B

Open	High	Low	Value	Volume
95.5¢	97.0¢	93.5¢	$1.424M	1.507M

Buyers (Bids)

No.	Vol.	Price($)
8	29390	93.5¢

Sellers (Offers)

Price($)	Vol.	No.
94.5¢	14089	2

View Market Depth

No.	Vol.	Price($)
6	24054	0.935
8	131583	0.930
4	65851	0.925
7	113334	0.920
9	97006	0.915

Price($)	Vol.	No.
0.945	1100	1
0.950	19026	2
0.955	27000	2
0.960	32869	2
0.965	35384	2

Last trade - 16.10pm 13/09/2024 (20 minute delay)

MSB (ASX) Chart

Fancy describing compassionate use for years as bad...

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Vulcan appoints investment bank and M&A veteran to board

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Utah authorities sign off on Anson's lithium extraction plans at Green River

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Fancy describing compassionate use for years as bad...

Top Stories

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Vulcan appoints investment bank and M&A veteran to board

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Utah authorities sign off on Anson's lithium extraction plans at Green River

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News